Fresh analysis reveals that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who halt conventional lifestyle plans.
Published data in a leading health publication demonstrates that while overweight people frequently drop a large proportion of their body weight while using the jabs, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing such treatments must be aware of the risk of quick weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to starting mass in about a year and a half.
Analyzing Approaches
The research, which reviewed 37 of trials involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.
The team emphasize that people who shed pounds through dieting usually experience a more gradual creep back—around 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Nutrition scientists believe the mechanism of the injections explains the heightened weight return.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production might result in the body to produce less of its endogenous GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making overeating a significant risk."
A Chronic Issue?
Health authorities advise the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians contend that, given the significant potential of relapse, the therapy should be considered ongoing.
This opinion is reinforced by pharmaceutical companies, who say that the results "highlight the chronic nature of excess weight," comparing it to managing conditions like high blood pressure.
Patient Testimonies
Individuals who have discontinued the jabs describe a intense return of cravings.
"I experienced a trigger that goes on and you're instantly ravenous," said an individual.
This challenge is worsened if patients have not established lasting dietary or behavioural modifications during treatment.
Significant Adoption
Survey data suggest that a significant number of adults in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is higher among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a standalone cure and long-term success hinges on combined lifestyle management.
